S 2397 – Massachusetts
Status: Inactive / DeadYear Introduced: 2019
Link: https://malegislature.gov/Bills/191/S2397
Relative to pharmaceutical access, costs and transparency. A pharmaceutical manufacturing company shall provide early notice to the commission if it plans to increase the wholesale acquisition cost of a: (i) brand-name drug by more than 20 per cent per wholesale acquisition cost unit during any 12-month period; or (ii) generic drug priced at $100 or more per wholesale acquisition cost unit by 200 per cent or more during any 12-month period.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
Associated Litigation:
No items found